PLEVA, L., P. KUKLA, J. ZAPLETALOVA and Ota HLINOMAZ. Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis. BMC Cardiovascular Disorders. London: Biomed Central Ltd, 2017, vol. 17, No 6, p. 1-9. ISSN 1471-2261. Available from: https://dx.doi.org/10.1186/s12872-017-0602-6.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis
Authors PLEVA, L. (203 Czech Republic), P. KUKLA (203 Czech Republic), J. ZAPLETALOVA (203 Czech Republic) and Ota HLINOMAZ (203 Czech Republic, guarantor, belonging to the institution).
Edition BMC Cardiovascular Disorders, London, Biomed Central Ltd, 2017, 1471-2261.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 1.812
RIV identification code RIV/00216224:14110/17:00099995
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1186/s12872-017-0602-6
UT WoS 000404166900001
Keywords in English In-stent restenosis; Paclitaxel-elution balloon; Drug-eluting stent
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 20/3/2018 17:07.
Abstract
Background: Our study aimed to compare the efficacy of seal-wing paclitaxel-eluting balloon catheters (PEB) with iopromide-coated PEB and everolimus-eluting stents (EES) for treating bare metal stent restenosis (BMS-ISR). Methods: We enrolled 64 patients with 69 BMS-ISR. The control group comprised patients from the iopromide-PEB and EES arms of a previous TIS study. The primary end-point was 12-month in-segment late lumen loss (LLL). Secondary end-points included incidence of binary in-stent restenosis and 12-month major adverse cardiac events (MACE). Results: Compared to iopromide-coated PEB, seal-wing PEB was associated with significantly higher 12-month LLL (0.30 vs. 0.02 mm; p < 0.0001), repeated binary restenosis (28.12% vs. 8.7%; p = 0.012), 12-month MACE (26.98% vs. 10.29%; p = 0.003), and target vessel revascularization (TVR; 20.63% vs. 7.35%; p = 0.009). Compared to EES, no significant differences were found in the 12-month LLL (0.30 vs. 0.19 mm; p = 1.000), repeated binary restenosis (28.12% vs. 19.12%; p = 0.666), 12-month MACE (26.98% vs. 19.12%; p = 0.102) or TVR (20.63% vs. 16.18%; p = 0.360). Conclusion: BMS-ISR treatment using seal-wing PEB led to significantly higher 12-month LLL, repeated binary restenosis, MACE, and TVR compared to iopromide-coated PEB. However, no significant differences were found in comparison with EES.
PrintDisplayed: 28/7/2024 08:31